Advaxis in talks to license HPV vacc

21 April 2009

Advaxis says that it has entered drug-licensing discussions for its flagship vaccine product, ADXS11-001 (formerly named Lovaxin-C), in  non-US markets.

ADXS11-001 is a therapeutic vaccine that treats active cancer, but at a  low cost because it is not formulated for a specific patient, the firm  claims, adding that, unlike currently-marketed prophylactic vaccines,  the drug treats women who have already developed cervical cancer as a  result of human papilloma-virus infection. Advaxis has already filed an  investigational New Drug Application for a Phase II trial in HPV-caused  cervical intraepithelial neoplasia, which is pre-cancerous.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight